Safety and pharmacokinetics of MM-302, a HER2-targeted antibody–liposomal doxorubicin conjugate, in patients with advanced HER2-positive breast cancer: a phase 1 dose-escalation study
Munster P, Krop IE, LoRusso P, Ma C, Siegel BA, Shields AF, Molnár I, Wickham TJ, Reynolds J, Campbell K, Hendriks BS, Adiwijaya BS, Geretti E, Moyo V, Miller KD. Safety and pharmacokinetics of MM-302, a HER2-targeted antibody–liposomal doxorubicin conjugate, in patients with advanced HER2-positive breast cancer: a phase 1 dose-escalation study. British Journal Of Cancer 2018, 119: 1086-1093. PMID: 30361524, PMCID: PMC6219487, DOI: 10.1038/s41416-018-0235-2.Peer-Reviewed Original ResearchConceptsOverall response rateAdverse eventsMM-302Breast cancerAdvanced HER2-positive breast cancerPhase 1 dose-escalation studyPhase 1 dose-escalation trialGrade 3/4 adverse eventsHER2-positive breast cancerAnthracycline-naïve patientsResultsSixty-nine patientsCommon adverse eventsDose-escalation studyDose-escalation trialPalmar-plantar erythrodysesthesiaMetastatic breast cancerFebrile neutropeniaMucosal inflammationPromising efficacyResponse rateTrastuzumabQ3wPatientsMonotherapyNeutropenia